Postviral Gastroparesis Associated With SARS-CoV-2 Infection in a Pediatric Patient

Rusch, Courtney M; Molleston, Jerome M.; Glasser, Matthew F.; Don, Steven; Kulkarni, Sakil

doi:10.1097/pg9.0000000000000195

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical studies demonstrated the ability of aqueous extract of C. cassia Presl bark (150 and 300 mg/kg) to enhance gastric emptying and to promote GI transit that are both delayed in some Long COVID‐19 patients, suffering from a complex pathological picture‐defined autoimmune GI dysmotility (Montalvo et al, 2022; Sebai et al, 2019). These effects may be relevant also in patients with SARS‐CoV‐2‐induced gastric motility alterations (Patel et al, 2022; Rusch et al, 2022). Furthermore, in vivo experiments have shown that water extracts derived from the bark of C. cassia (150 mg/kg) significantly reduce the extent of gastric mucosa injuries caused by indomethacin, NSAIDs, ethanol, and ethanol/hydrochloric acid.…”

Section: The Phytocomplexmentioning

confidence: 99%

Long COVID‐19 gastrointestinal related disorders and traditional Chinese medicine: A network target‐based approach

Mattioli,

Frosini,

Corazza

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

The significant number of individuals impacted by the pandemic makes prolonged symptoms after COVID‐19 a matter of considerable concern. These are numerous and affect multiple organ systems. According to the World Health Organization (WHO), prolonged gastrointestinal issues are a crucial part of post‐COVID‐19 syndrome. The resulting disruption of homeostasis underscores the need for a therapeutic approach based on compounds that can simultaneously affect more than one target/node. The present review aimed to check for nutraceuticals possessing multiple molecular mechanisms helpful in relieving Long COVID‐19‐specific gastrointestinal symptoms. Specific plants used in Keywords Chinese Medicine (TCM) expected to be included in the WHO Global Medical Compendium were selected based on the following criteria: (1) they are widely used in the Western world as natural remedies and complementary medicine adjuvants; (2) their import and trade are regulated by specific laws that ensure quality and safety (3) have the potential to be beneficial in alleviating intestinal issues associated with Long COVID‐19. Searches were performed in PubMed, Elsevier, Google Scholar, Scopus, Science Direct, and ResearchGate up to 2023. Cinnamomum cassia, Glycyrrhiza uralensis, Magnolia officinalis, Poria cocos, Salvia miltiorrhiza, Scutellaria baicalensis, and Zingiber officinalis were identified as the most promising for their potential impact on inflammation and oxidative stress. Based on the molecular mechanisms of the phytocomplexes and isolated compounds of the considered plants, their clinical use may lead to benefits in gastrointestinal diseases associated with Long COVID‐19, thanks to a multiorgan and multitarget approach.

show abstract

Section: The Phytocomplexmentioning

confidence: 99%

Long COVID‐19 gastrointestinal related disorders and traditional Chinese medicine: A network target‐based approach

Mattioli,

Frosini,

Corazza

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…After investigation of the epidemiologic links, antibody testing, and a clinical course, the patient was diagnosed with post-viral GP due to COVID-19. She was treated with supportive care and prokinetic agents and demonstrated symptom resolution and the near normalization of gastric emptying by the time of her 1-month follow-up [ 112 ].…”

Section: Exogenous Infections As Trigger Of Gastroparesismentioning

confidence: 99%

Gastroparesis: The Complex Interplay with Microbiota and the Role of Exogenous Infections in the Pathogenesis of the Disease

et al. 2023

View full text Add to dashboard Cite

Gastroparesis (GP) is a disorder of gastric functions that is defined by objective delayed gastric emptying in the absence of mechanical obstruction. This disease is characterized by symptoms such as nausea, post-prandial fullness, and early satiety. GP significantly impacts patients’ quality of life and contributes to substantial healthcare expenses for families and society. However, the epidemiological burden of GP is difficult to evaluate, mainly due its significant overlap with functional dyspepsia (FD). GP and FD represent two similar diseases. The pathophysiology of both disorders involves abnormal gastric motility, visceral hypersensitivity, and mucosal inflammation. Moreover, both conditions share similar symptoms, such as epigastric pain, bloating, and early satiety. The latest evidence reveals that dysbiosis is directly or indirectly connected to gut–brain axis alterations, which are the basis of pathogenesis in both FD and GP. Furthermore, the role of microbiota in the development of gastroparesis was demonstrated by some clinical studies, which found that the use of probiotics is correlated with improvements in the gastric emptying time (GET). Infections (with viruses, bacteria, and protozoa) represent a proven etiology for GP but have not been sufficiently considered in current clinical practice. Previous viral infections can be found in about 20% of idiopathic GP cases. Moreover, delayed gastric emptying during systemic protozoal infections represents a huge concern for compromised patients, and few data exist on the topic. This comprehensive narrative review analyzes the relationship between microorganisms and GP. We explore, on the one hand, the correlation between gut microbiota dysbiosis and GP pathogenesis, including treatment implications, and, on the other hand, the association between exogenous infections and the etiology of the disease.

show abstract

A Three-way Attack on the Gastrointestinal System- COVID-19, Ehler-Danlos Syndrome, and Anorexia Nervosa Leading to Severe Gastroparesis in a Young Female

Jivtesh,

Shruti,

Alka

2024

Glob J Infect Dis Clin Res

View full text Add to dashboard Cite

A 28-year-old female with a past medical history of Major Depressive Disorder, Generalized Anxiety Disorder, Anorexia Nervosa, Chronic Pain Syndrome, and Gastro-esophageal Reflux presented to our clinic for establishing care in November 2022 with severe gastric dysmotility ever since contracting COVID-19 virus in December 2021. The patient’s symptoms were refractory to Erythromycin and metoclopramide therapy. A GI motility study in February 2022 showed delayed gastric emptying based on which the patient was diagnosed with Post COVID Gastroparesis. Based on an extensive clinical review of the patient’s past medical and surgical history, the patient was found to have cumulative symptoms of GERD, joint instability, abdominal hernia and chronic neuropathic pain, raising the suspicion of Ehler-Danlos syndrome- Hypermobility type. Given the failure of treatment with prokinetic agents and over 60 pounds of weight loss the patient underwent Percutaneous Endoscopic Gastrostomy-Jejunostomy in August 2022, the patient was started on Organic Tube Feeding Formula. To this date, the patient is using the PEG-J for feeding and remains nil per oral. Multiple trials of reintroducing oral feeding have been attempted but the patient still is unable to tolerate oral feeds completely and continues to complain of early satiety, nausea, and vomiting on reintroducing feeds.

show abstract

Postviral Gastroparesis Associated With SARS-CoV-2 Infection in a Pediatric Patient

Cited by 3 publications

References 10 publications

Long COVID‐19 gastrointestinal related disorders and traditional Chinese medicine: A network target‐based approach

Long COVID‐19 gastrointestinal related disorders and traditional Chinese medicine: A network target‐based approach

Gastroparesis: The Complex Interplay with Microbiota and the Role of Exogenous Infections in the Pathogenesis of the Disease

A Three-way Attack on the Gastrointestinal System- COVID-19, Ehler-Danlos Syndrome, and Anorexia Nervosa Leading to Severe Gastroparesis in a Young Female

Contact Info

Product

Resources

About